Roche Holding Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Roche Holding sono diminuiti a un tasso medio annuo di -3.4%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 12.9%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 0.02%. Il ritorno sul capitale proprio di Roche Holding è 35% e ha margini netti di 17.5%.

Informazioni chiave

-3.4%

Tasso di crescita degli utili

-1.7%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	16.3%
Tasso di crescita dei ricavi	-0.02%
Rendimento del capitale proprio	35.0%
Margine netto	17.5%
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Ripartizione dei ricavi e delle spese

Come Roche Holding guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

SWX:RO Ricavi, spese e utili (CHF Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	60,581	10,619	13,346	13,381
31 Mar 24	60,511	11,059	13,416	13,463
31 Dec 23	60,441	11,498	13,486	13,545
30 Sep 23	61,486	11,263	13,738	13,669
30 Jun 23	62,530	11,028	13,894	13,793
31 Mar 23	64,172	11,725	13,793	13,696
31 Dec 22	65,814	12,421	13,691	13,599
30 Sep 22	66,716	13,539	13,262	13,592
30 Jun 22	67,617	14,657	12,833	13,585
31 Mar 22	66,734	14,294	12,405	13,804
31 Dec 21	65,850	13,930	11,977	14,022
30 Sep 21	63,974	13,975	12,037	13,747
30 Jun 21	62,098	14,019	12,097	13,472
31 Mar 21	61,221	14,157	12,026	13,019
31 Dec 20	60,343	14,295	11,954	12,566
30 Sep 20	61,361	13,626	12,289	12,382
30 Jun 20	62,378	12,957	12,624	12,198
31 Mar 20	63,065	13,227	12,904	12,061
31 Dec 19	63,751	13,497	13,183	11,923
30 Sep 19	62,736	12,654	13,275	11,702
30 Jun 19	61,721	11,810	12,933	11,480
31 Mar 19	60,609	11,155	12,800	11,337
31 Dec 18	59,497	10,500	12,667	11,194
30 Sep 18	58,611	10,483	12,641	11,005
30 Jun 18	57,725	10,465	12,615	10,815
31 Mar 18	56,736	9,549	12,322	10,672
31 Dec 17	55,746	8,633	12,029	10,529
30 Sep 17	54,961	9,154	11,148	10,411
30 Jun 17	54,176	9,675	10,266	10,293
31 Mar 17	53,406	9,626	10,305	10,172
31 Dec 16	52,636	9,576	10,343	10,050
30 Sep 16	52,109	9,332	10,655	9,975
30 Jun 16	51,581	9,087	10,966	9,900
31 Mar 16	50,992	8,975	10,953	9,678
31 Dec 15	50,403	8,863	10,940	9,455
30 Sep 15	50,364	8,908	10,978	9,305
30 Jun 15	50,324	8,953	11,004	9,155
31 Mar 15	50,095	9,143	10,924	9,068
31 Dec 14	49,866	9,332	10,844	8,980
30 Sep 14	49,300	10,044	10,698	8,899
30 Jun 14	48,733	10,756	10,551	8,817
31 Mar 14	48,673	10,960	10,569	8,787
31 Dec 13	48,612	11,164	10,587	8,756

Guadagni di qualità: RO ha un grande una tantum perdita di CHF3.8B che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 30th June, 2024.

Margine di profitto in crescita: Gli attuali margini di profitto netti di RO (17.5%) sono inferiori rispetto allo scorso anno (17.6%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di RO sono diminuiti del 3.4% all'anno negli ultimi 5 anni.

Accelerare la crescita: RO ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.

Guadagni vs Settore: RO ha avuto una crescita negativa degli utili ( -3.7% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Pharmaceuticals ( 9.5% ).

Rendimento del capitale proprio

ROE elevato: Sebbene il Return on Equity ( 34.96% ) di RO sia elevato, questa metrica è distorta a causa del loro elevato livello di debito.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/23 01:31
Prezzo dell'azione a fine giornata	2024/12/23 00:00
Guadagni	2024/06/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Roche Holding AG è coperta da 59 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Kamla Singh	AlphaValue
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research

Roche Holding Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Recent updates

Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions

New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma

Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran